TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Zydus Lifesciences Limited ( (IN:ZYDUSLIFE) ) has issued an announcement.
Zydus Lifesciences Limited has announced that it received an Establishment Inspection Report (EIR) from the USFDA for its oncology injectable facility in SEZ1, Ahmedabad. The facility’s classification has been upgraded from Official Action Indicated (OAI) to Voluntary Action Indicated (VAI), reflecting improvements in compliance and potentially enhancing the company’s reputation and operational capabilities in the pharmaceutical industry.
More about Zydus Lifesciences Limited
Zydus Lifesciences Limited operates in the pharmaceutical industry, focusing on the development and manufacturing of a wide range of healthcare products, including oncology injectables. The company is known for its commitment to innovation and quality in the healthcare sector, catering to both domestic and international markets.
Average Trading Volume: 49,609
Technical Sentiment Signal: Strong Buy
Current Market Cap: 1043.5B INR
For a thorough assessment of ZYDUSLIFE stock, go to TipRanks’ Stock Analysis page.